Fibroblast Growth Factor Receptor 1&2 Assay Targets Cell Growth & Tumor Progression State College, PA (31 August 2021) – INDIGO Biosciences, the recognized industry leader in nuclear receptor research, has expanded their robust preclinical testing portfolio to include a new Fibroblast Growth Factor Receptor 1&2 (FGFR1/2) assay primarily implicated in diabetes, kidney disease, and theRead More
INDIGO Biosciences Announces Addition of TPOR Assay to Pre-Clinical Portfolio
Thrombopoietin Receptor Indicated in Anemia & Blood Cancer Treatment Development State College, PA (10 August 2021) – INDIGO Biosciences, the recognized industry leader in nuclear receptor research, has expanded its pre-clinical portfolio to include the Thrombopoietin Receptor (TPOR). Responsible for platelet production, TPOR is primarily used in developing treatments related to familial aplastic anemia andRead More
INDIGO Biosciences Expands Portfolio to Include Cannabinoid Type 1 Receptor
CB1R Assay Implicated in Cancer Therapies and Neurological Disorders State College, PA (13 July 2021) – INDIGO Biosciences, the recognized industry leader in nuclear receptor research, has expanded their robust testing portfolio to include a new Cannabinoid Type 1 Receptor (CB1R) assay, primarily used in developing cancer side effect-related treatments and implicated in the developmentRead More
INDIGO Biosciences Expands Preclinical Portfolio for Anemia and Oncology Research
Erythropoietin Receptor Assay Targets Red Blood Cell Development and Production State College, PA (20 April 2021) – INDIGO Biosciences, the recognized industry leader in nuclear receptor research, has expanded their robust preclinical testing portfolio to include a new Erythropoietin Receptor (EPOR) assay primarily used in the treatment of anemia and implicated in the development ofRead More